Recent results from a phase 2 clinical research suggest that retatrutide®, if permitted, may work better than well-known weight loss drugs like Wegovy®. Talk to one of our reputable, board-certified primary care physicians to find out more about this efficient substitute medication for weight loss.
Eli Lilly developed the drug Retatrutide®, which is given as an injection once a week. The medication is currently in phase 2 trials to assess how well it works for controlling type 2 diabetes, treating obesity, and maybe treating other illnesses such as non-alcoholic fatty liver disease (NAFLD).
These clinical trials are being conducted following the rapid rise in popularity of the drug semaglutide. Semaglutide, marketed under the names Ozempic® and Wegovy®, is mostly used to treat diabetes, while it can also be a very successful weight-loss medication.
Tirzepatide, often known as Mounjaro®, is another promising medication for diabetes.
Semaglutide and tirzepatide both influence the body’s glucagon-like peptide-1 (GLP-1) receptor agonists. In other words, they mimic the actions of a hormone called GLP-1, which is essential for controlling blood sugar levels and encouraging satiety, or the sensation of being full. These drugs can enhance glycemic management and provide a sensation of fullness by activating GLP-1 receptors.
In the retatrutide® phase 2 trial, which was reported in the New England Journal of Medicine (NEJM), 338 obese individuals were assigned to receive a placebo or one of four retatrutide® doses: 1 mg, 4 mg, 8 mg, or 12 mg. Interestingly, after 48 weeks of treatment, every patient who received the highest dose of retatrutide® lost at least 5% of their body weight. About one in four individuals saw a weight loss of at least 30%.
The results of a different trial involving 281 adults with type 2 diabetes were published in the Lancet in June 2023. The study revealed that after nine months of treatment, those getting the highest dose of retatrutide® lost almost 17% of their body weight. These encouraging findings are noteworthy in part because weight loss is frequently difficult for those who have type 2 diabetes and obesity.
Depending on the particular health situation, the following are some regularly suggested alternatives:
Contrave®
Xenical® (Orlistat)
Wegovy®
Zepbound™
Trulicity®
Invokamet (canagliflozin metformin)
Glucophage (metformin)
Victoza®
Mounjaro®
Ozempic®
Rybelsus®
The Food and Drug Administration (FDA) is anticipated to take several years to approve retatrutide®. The main cause of this is the need to finish lengthy phase three trials, which are expected to last until 2025.
Retatrutide® is made by the well-known pharmaceutical business Lilly, formally known as Eli Lilly and business. They treat cancer, diabetes, endocrinology, cardiovascular disease, and more with their wide spectrum of drugs. Among other things, they produce the well-known type 2 diabetes medications Trulicity® (dulaglutide) and Mounjaro® (tirzepatide).
The term “Retatrutide®” describes a peptide that functions on three different receptors: the glucagon receptor (GCGR), the glucose-dependent insulinotropic polypeptide receptor (GIPR), and the glucagon-like peptide-1 receptor (GLP-1R). The peptide is known as LY3437943. Blood sugar regulation and appetite regulation are impacted by activity at these receptors. Because of its special qualities, retatrutide® is a good option for obesity research.
How much weight can you lose on retatrutide®?
Retatrutide® assisted patients in a clinical trial in losing an average of up to 24 percent of their body weight, or as much as 60 pounds. When compared to currently available obesity treatments, such as type 2 diabetes meds and weight loss pills like Ozempic® and Wegovy®, this experimental drug shows a more significant reduction in body weight.
GLP-1 receptor agonists help people lose weight by reducing brain signals associated with hunger and increasing feelings of fullness. Likewise, GIP agonists control energy balance by communicating via brain and fat tissue receptors.
We recommend everyone to sign up for an online appointments instead of in-person visits.
Mon- Sun (8 AM to 10 PM) Stay safe. Stay healthy!